LGD-4033 and MENT Interaction

Synergistic
Mechanism-based 49% confidence

LGD-4033 and MENT have a synergistic interaction with 49% confidence. MENT helps manage estrogen conversion from LGD-4033. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

MENT

19-Nor Anabolic Steroid | Experimental TRT Alternative

MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN.

Half-life: ~40 minutes (acetate ester) Typical dose: 5-25 mg/day (acetate) anabolic, sexual health
5 alpha reductaseandrogen receptorepo receptorestrogen receptor androgenicaromatase inhibitorblood pressure raisingcarcinogenic risk
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
moderate

Shared Safety Flags

2x 2 androgenic compounds (LGD-4033, MENT). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds raise blood pressure (LGD-4033, MENT). Monitor BP daily and consider cardiovascular support.
2x 2 compounds share the carcinogenic-risk safety flag (LGD-4033, MENT). Monitor accordingly.
2x 2 estrogenic compounds (LGD-4033, MENT). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 HPTA-suppressive compounds (LGD-4033, MENT). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (LGD-4033, MENT). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (LGD-4033, MENT). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with MENT?

Yes, LGD-4033 and MENT can generally be taken together. MENT helps manage estrogen conversion from LGD-4033. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.

Is LGD-4033 and MENT safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: androgenic, blood pressure raising, carcinogenic risk, estrogenic, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between LGD-4033 and MENT?

MENT helps manage estrogen conversion from LGD-4033. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen. This assessment has 49% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and MENT?

LGD-4033 has a half-life of ~24-36 hours and MENT has a half-life of ~40 minutes (acetate ester). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs MENT

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.